# Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes

> **NCT00633997** · PHASE1,PHASE2 · TERMINATED · sponsor: **Novartis** · enrollment: 22 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Vildagliptin
- **DRUG:** Vildagliptin

## Key facts

- **NCT ID:** NCT00633997
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2008-12
- **Final completion:** —
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** After analysis of the existing data, it was determined that additional skin biopsy samples would not be required to determine study outcome.
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00633997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00633997, "Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00633997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*